| Filed On | Filing |
|---|---|
| 16 Nov 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
Pre-Funded Warrants to Purchase 50,350,000 Shares of Common Stock |
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition; Other Events
- Received FDA approval of CGuard® Prime for Transcarotid Arterial Revascularization (TCAR) procedures, expected to approximately double the U.S. addressable market - |
| 12 Nov 2026 |
8-K: Regulation FD Disclosure; Other Events
- Approval doubles the CGuard Prime platform’s total addressable market in the U.S. with additional access to over 35,000 TCAR procedures annually – |
| 21 Sep 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
THIS SERIES J COMMON STOCK PURCHASE WARRANT AMENDMENT (this “Amendment”) is entered into as of September 21, 2026, by and between InspireMD, Inc., a Delaware corporation (the “Company”), and the holder identified on the signature page he... |
| 17 Aug 2026 |
8-K: Results of Operations and Financial Condition
- Company to host investor conference call today, August 17th, at 8:30am EDT - |
| 29 Jul 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On July 23, 2026, InspireMD, Inc. (the “Company”) provided notice to Shane Gleason, the Company’s Chief Commercial Officer, that his position has been eliminated. His last day of employment with the Company will be July 31, 2026. |
| 23 Jul 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
On July 17, 2026, InspireMD, Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the minimum b... |
| 02 Jul 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On June 26, 2026, Mr. Raymond W. Cohen, a Class III member of the board of directors (the “Board”) of InspireMD, Inc. (the “Company”), a member of the Audit Committee of the Board and a member of the Compensation Committee of the Board, ... |
| 11 Jun 2026 |
8-K: Regulation FD Disclosure
InspireMD Announces 30-Day Results from the CGUARDIANS II Clinical Trial of the CGuard Prime 80 cm Implant for Use in TCAR Procedures |
| 03 Jun 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders
InspireMD, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware, does hereby certify that: |
| 22 May 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On May 20, 2026, Mr. Paul Stuka notified InspireMD, Inc. (the “Company”) of his decision to not seek reelection as a Class I director of the Board of Directors of the Company (the “Board”) at the Company’s 2027 Annual Meeting of Stockhol... |
| 04 May 2026 |
8-K: Results of Operations and Financial Condition
- Reports total Q1 2026 revenue of $3.4 million, representing year-over-year growth of 122% - |
| 01 May 2026 |
8-K: Regulation FD Disclosure; Other Events
- Strong clinical demand continues in Q1 2026 with global year-over-year unit sales growth of 53% and quarter-over-quarter U.S. unit sales growth of 34% - |
| 03 Apr 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
As further set forth in this agreement (this “Agreement”), InspireMD, Inc., a Delaware corporation (the “Company”), proposes to issue and sell from time to time through BTIG, LLC (the “Agent”), as sales agent, the Company’s common stock,... |
| 18 Mar 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Miami, FL — March 18, 2026 – InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced financial and operating results for the fourth ... |
| 04 Mar 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On February 27, 2026, InspireMD, Inc. (the “Company”) provided a notice of dismissal to Andrea Tommasoli, the Company’s Chief Operating Officer. |
| 19 Dec 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On December 17, 2025, Kathryn Arnold, a Class III member of the board of directors of InspireMD, Inc. (the “Board” and the “Company”, respectively), a member of the compensation committee of the Board (the “Compensation Committee”), the ... |
| 04 Nov 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Successful initial CGuard Prime U.S. commercial launch drives record quarterly revenue |
| 17 Sep 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Miami, Florida — September 17, 2025 – InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of Dan Dearen to its B... |
| 05 Aug 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Management to host investor conference call today, August 5th, at 8:30am ET --- |
Loading...